TrialFrontiers in immunology2026

VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.

Bernard Benichou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.